DTIL VS SRTS Stock Comparison

PerformanceSentimentTechnicalsEarningsProfitVolatilityAnalyst Price Targets
PerformanceSentimentTechnicalsEarningsProfitVolatilityAnalyst Price Targets

Performance

DTIL
10/100

DTIL returned -79.21% in the last 12 months. Based on SPY's performance of -20.66%, its performance is below average giving it a score of 10 of 100.

SRTS
10/100

SRTS returned -74.14% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

DTIL
68/100

DTIL had a bullish sentiment score of 68.05% across Twitter and StockTwits over the last 12 months. It had an average of 8.75 posts, 4.76 comments, and 13.29 likes per day.

SRTS
65/100

SRTS had a bullish sentiment score of 64.54% across Twitter and StockTwits over the last 12 months. It had an average of 2.84 posts, 2.38 comments, and 1.78 likes per day.

Technicals

DTIL
14/100

DTIL receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

SRTS
21/100

SRTS receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

DTIL
10/100

DTIL has missed earnings 5 times in the last 20 quarters.

SRTS
10/100

SRTS has missed earnings 6 times in the last 20 quarters.

Profit

DTIL
10/100

Out of the last 20 quarters, DTIL has had 1 profitable quarters and has increased their profits year over year on 1 of them.

SRTS
44/100

Out of the last 20 quarters, SRTS has had 10 profitable quarters and has increased their profits year over year on 5 of them.

Volatility

DTIL
32/100

DTIL has had a lower than average amount of volatility over the last 12 months giving it a score of 32 of 100.

SRTS
42/100

SRTS has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.

Analyst Price Targets

DTIL

"Analyst Price Targets" not found for DTIL

SRTS
75/100

2 analysts offer 12-month price targets for SRTS. Together, they have an average target of 16, the most optimistic target put SRTS at 16 within 12-months and the most pessimistic has SRTS at 16.

All score calculations are broken down here to help you make more informed investing decisions

Precision BioSciences, Inc. Common Stock Summary

Nasdaq / DTIL
Healthcare
Biotechnology
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Sensus Healthcare, Inc Summary

Nasdaq / SRTS
Healthcare
Medical - Devices
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.